. Neonatal hypoglycaemia in infants of diabetic mothers given sulphonylurea drugs in pregnancy. Three infants whose diabetic mothers were given chlorpropamide and one infant whose diabetic mother was given acetohexamide up to the time of delivery were studied in the neonatal period because each became severely hypoglycaemic. The sulphonylurea drugs given to the mother crossed the placenta, and fetal plasma concentrations were in the therapeutic range for adults with diabetes mellitus. Each baby had severe hyperinsulinaemia resulting in profound hypoglycaemia. These acutely ill infants needed vigorous and prolonged treatment to correct the hypoglycaemia. In two infants exchange transfusion was performed to remove the drug. These sulphonylurea drugs should not be used to control diabetes mellitus in pregnancy.
investigations to allow direct comparison to be made between the infants., The clinical and laboratory data of each baby are presented in the case histories.
Blood or plasma glucose levels were measured by a glucose oxidase method and values of 20 mg./100 ml. or less were considered to be hypoglycaemic. Serum or plasma insulin levels were measured by immunoassay (Hales and Randle, 1963; Morgan and Lazarow, 1963; Tiernan, Kemball, and Soeldner, 1968) . Human insulin standards were used in Cases 1, 2, and 3; a beef insulin standard with a non-discriminatory antibody was used in Case 4. Urinary immunoreactive insulin was measured in Case 3 (Rubenstein et al., 1967) . No mother had received insulin before the birth of the baby reported in this study. Plasma levels of chlorpropamide were measured according to Toolan and Wagner (1959) and acetohexamide and its metabolite hydroxyhexamide according to Spingler (1957) .
All intravenous or intra-arterial glucose tolerance tests (GTT) were performed by giving glucose 0 5 g./kg.
in one to two minutes. Blood samples were taken before and at various times in the subsequent hour.
The glucose disappearance constant (Kt) was calculated (Greville, 1943) and is expressed throughout as percentage per minute. In the oral leucine tolerance test performed in Case 3 L-leucine (120 mg./kg.) was given by gavage during continuous slow intragastric infusion of glucose 1 1 g./kg. per hour (Bower, Rayner, and Stimmler, 1967 (Farquhar, 1959) . At 1 and at 3 hours of age blood glucose levels were 9 mg./100 ml.
At 7 hours, when the blood glucose level was 15 mg./ 100 ml., he developed generalized convulsions. Treatment was started by the injection of glucose 0 5 g./kg. into the umbilical artery over a 2-minute period. Blood glucose and serum insulin levels were measured beforehand and during the next 30 minutes. The glucose disappearance rate was abnormally fast (Table I) . At 10 hours of age the serum level of acetohexamide was 4-4 mg./100 ml. and its actively hypoglycaemic metabolite hydroxyhexamide 5-4 mg./100 ml. The acetohexamide level was within the adult therapeutic range of 2-1-5-6 mg./100 ml. (Sheldon, Anderson, and Stoner, 1965) . Despite the subsequent infusion of large amounts of glucose, hypoglycaemic blood glucose levels were recorded on five occasions in the first two days of life. Artificial milk feeds were started on the third day of life but intravenous glucose could not be discontinued until the fifth day. A second parenteral GTT via a peripheral vein was performed on the sixth day. Glucose disappearance was slower than before but still abnormally fast (Table II) . Clinical progress at this time was normal however and continued to be so until the age of 9 months when he was last seen.
The (mg./100 ml.) (,uU/ml.) (mg./l00 ml.) (gtU/ml.) (mg./100 ml.) (,LU/ml.) (mg./100 ml.) (JU/ml.) (mg./100 ml.) (,uU/ml.) (mg./100 ml.) (WU/ml.) (mg./100 ml.) (,uU/ml.) (mg./100 ml.) (gU/ml.) (Table I) . The serum insulin level was high at the start of the test and rose further after the glucose injection. The serum chlorpropamide level during the test was 2-1 mg./100 ml., near the therapeutic range for adults, 3 0-14-0 mg./I00 ml. (Sheldon et al., 1965) . Despite an increased intravenous glucose intake to provide 100 cal./kg. per 24 hours, a prednisone dose of 24 mg. per 24 hours and the administration of glucagon 6 hourly, she remained hypoglycaemic and it was four days before her drip could be discontinued. At 10 days, reduction in the dose of prednisone and glucagon was associated with apnoeic spells during which blood glucose levels of 11 and 15 mg./100 ml. were recorded. On the eleventh day chlorpropamide was still detectable in the blood at a concentration of 0.5 mg./100 ml. All treatment was discontinued by the age of 4 weeks and the baby remained well until, at 5 weeks, she died suddenly following inhalation of vomit. At necropsy the weight of the heart and liver were increased. Most of the islets of Langerhans were normal, but a few in the tail of the pancreas were hypertrophied. The brain showed slight ventricular dilatation with small patches of periventricular leucomalacia. In the white matter of the cerebellum, brainstem, and spinal cord there was obvious fibrous gliosis. The nerve cells were not grossly affected. It was uncertain whether these changes resulted from birth asphyxia or postnatal hypoglycaemia (Anderson, Milner, and Strich, 1967 This caused a fall in the serum chlorpropamide level from 1*1 to 0*5 mg./100 ml. A second umbilical intravenous GTT revealed very high serum insulin levels and a faster glucose disappearance than before (Table II) . Most remarkable of all were the 24-hour urinary insulin levels for the first two days of life. At 4240 and 954 IAU/mg. creatinine, respectively, these insulin levels were more than 100 times greater than those measured in infants of diabetic mothers treated with diet or insulin during pregnancy (Schiff, 1968) .
Because of the possibility that exposure to chlorpropamide during fetal life might have caused leucinesensitive hyperinsulinism as occurs in adults (Fajans et al., 1963) , protein-containing foods were excluded from the infant's diet. He was fed on a mixture of glucose and arachis oil, and by the fifth day it was possible to stop intravenous therapy. Most blood glucose levels were in the normal range thereafter, but occasional values of less than 20 mg./100 ml. were recorded in the following three weeks. During the same period the urinary insulin excretion fell to low levels, 12 -5 ,uU/mg. creatinine (Lowy and Schiff, 1968 creatinine. An oral leucine tolerance test was performed at the age of 4 weeks, 7 hours after the last milk feed. There was an obvious rise in serum insulin levels after the leucine load, but no fall in the blood glucose level (Table III (Milner and Wright, 1966) . Case 4 had a higher insulin response and a smaller rise in plasma glucose than the mean change in the earlier study (Table IV) . Chlorpropamide 13-3 mg., was removed by the exchange transfusion. Despite this, the plasma concentration only fell from 2-9 to 1 9 mg./ 100 ml. from the start to the 400 ml. point in the transfusion, indicating that some of the drug was stored extravascularly. After the transfusion the baby was fed with 40 ml. half strength full-cream milk 3-hourly, and showed no further clinical abnormality apart from one spell of 'jitteriness'. A third GTT performed at 54 hours still showed, but to lesser degree, the abnormalities noted in the second test (Table II) . The plasma chlorpropamide level was 1-6 mg./100 ml. Feeds were subsequently dissolved in 10°, fructose and the baby became less drowsy and lethargic. He remained clinically normal thereafter and fructose supplements were discontinued on the sixth day. Discussion Each of the 4 infants reported here had been exposed to a sulphonylurea drug for the last two or more weeks in utero and was born with significant levels of the drug in the circulation. Each had protracted symptomatic hypoglycaemia due to obvious hyperinsulinism in the immediate postnatal days. Prolonged intravenous treatment with glucose was of prime importance in treatment. The addition of fructose to the diet of one infant and the exclusion of leucine from the diet of another infant both appeared to be important measures in diminishing the stimuli to insulin secretion. In 2 infants exchange transfusion removed appreciable amounts of chlorpropamide from both intra-and extravascular pools and was thought to have shortened the infants' illness.
It is known that tolbutamide and chlorpropamide cross the human placenta to reach therapeutic levels in the newborn infant (Miller, Wishinsky, and Thompson, 1962; Zucker and Simon, 1968 (Cardell, 1953) . As sulphonylurea drugs are also known to stimulate 5-cell hyperplasia, they may be expected to augment the effects of maternal diabetes on fetal islet cell development in this respect. Moreover, in the first days of life, when hepatic drug metabolism is immature, an obvious prolongation of half-life has been demonstrated for tolbutamide (Nitowsky, Matz, and Berzofsky, 1966) . For chlorpropamide, which even in adults has a half-life of 36 hours (Kelly and Johnson, 1959) , five times that of tolbutamide or acetohexamide, such a delay in metabolism is likely to be particularly dangerous.
The presence of measurable levels ofchlorpropamide in the blood of Case 2 as late as the 11th day of life appears to confirm this prediction. Thus, sulphonylurea drugs given during pregnancy may not only act by stimulating (-cell hyperplasia in utero, but may also have a prolonged pharmacological effect postnatally.
In the first few hours after birth most infants of insulin-treated diabetic mothers have profound but transient and asymptomatic hypoglycaemia (Cornblath and Schwartz, 1966; Farquhar and Isles, 1968) . The 4 infants presented here differed from them not only in the prolonged duration of hypoglycaemia but in the presence of severe symptoms. Though severe birth asphyxia may result in reduced hepatic carbohydrate stores and hypoglycaemia in the immediate postnatal period (Shelley and Neligan, 1966) and may, therefore, have contributed to the disturbance in Cases 2 and 4, it cannot be implicated at any stage in Cases 1 and 3, nor in the prolonged illness of any of the 4 infants. In them the major cause of hypoglycaemia was undoubtedly increased secretion of insulin.
Immunoreactive insulin levels cannot be measured in the serum of infants of diabetic mothers treated with insulin because circulating antibodies to the exogenous hormone interfere with the assay system. Thus, the serum levels of insulin in our 4 infants can only be compared with those infants of diabetic mothers controlled by diet alone. None of the 11 such infants previously studied by similar GTT techniques (Tiernan, Kemball, and Smith, 1968) showed the sustained hyperinsulinism in the presence of hypoglycaemia which was such a distinctly abnormal feature of the 4 infants described here. Anti-insulin antibodies are not excreted in the urine of infants of insulin-treated mothers. The urine insulin levels of a group of such infants (Schiff, 1968) are therefore a valid comparison for the remarkably high values found in Case 3. Thus, these 4 infants who were chronically exposed to sulphonylurea drugs showed evidence of increased and inappropriate insulin secretion both when their serum levels were compared with those of infants of diet-controlled mothers and when urine levels were compared with those of infants of insulincontrolled mothers.
Studies of the effects of sulphonylurea drugs on the outcome of diabetic pregnancy have differed in their conclusions and have been reviewed by Adam and Schwartz (1968) . Some centres have shown no increase in perinatal mortality and morbidity (Dolger, Bookman, and Nechemias, 1962; Douglas and Richards, 1967; Sutherland et al., 1970) . Others have expressed a cautious view (Malins et al., 1964) , and finally one study has shown a rise in perinatal mortality in infants of chlorpropamide-treated mothers (Jackson et al., 1962) . In addition there have been several isolated reports of severe hypoglycaemic illness in infants of mothers given tolbutamide (Nitowsky et al., 1966, and personal communication) and chlorpropamide (Zucker and Simon, 1968; Farquhar and Isles, 1968) . It remains a mystery why some infants of mothers given sulphonylurea drugs are severely affected while others appear to be healthy. Symptomatic hypoglycaemia of the newborn carries a considerable risk of death or severe cerebral damage in survivors (Haworth et al., 1963; Brown and Wallis, 1963; Anderson et al., 1967) . Till there is some means of detecting in advance those infants who would be adversely affected in this way, it seems to us that the grave hazards of sulphonylurea treatment are such that these drugs should be avoided in the obstetric management of diabetic women.
